Global Pharmacogenomics (PGx) Market Analysis: Focus on Ecosystem Players (Diagnostic Test, Pharmaceutical & Others), Therapeutic Applications (Oncology, Cardiovascular & Others), and Geography – Estimation & Forecast 2016-2022

Global Pharmacogenomics (PGx) Market Analysis: Focus on Ecosystem Players (Diagnostic Test, Pharmaceutical & Others), Therapeutic Applications (Oncology, Cardiovascular & Others), and Geography – Estimation & Forecast 2016-2022

  • April 2016 •
  • 322 pages •
  • Report ID: 4818028 •
  • Format: PDF
Description
Rapid advancement and innovation of new healthcare technologies such as next generation sequencing, High Throughput Screening (HTS), and Digital Polymerase Chain Reaction (PCR) are developing a strong base for the growth of Pharmacogenomics (PGx) market. The completion of first human genome project in 1990s has created a platform for the development of further enhanced Pharmacogenomics solutions. PGx is not a modernized market yet, however, the increasing demand for precision medicine, targeted therapeutics and increasing cases of adverse drug reactions are some of the major factors which led to a tremendous growth rate in the past few years.

Since the announcement of ‘Precision Medicine Initiative’ by the President Barack Obama in January 2015, a large number of Research and Development (R&D) programs has been taken up for the developing precise drugs, targeted therapeutics, and laboratory tests which required Pharmacogenomics analysis. At present, government initiatives are focused towards launching a large number of PGx test & drugs, controlling the increasing level of genetic disorders, and integrating advanced technologies to fulfill the unmet needs of the patients. Most of the developments taking place in the present scenario are mainly related to oncology & cardiovascular diseases, but it is anticipated that it may target almost all therapeutic areas affected by genetic mutations.

Government regulations and standards are sustaining the growth and development of the PGx market. The main aim of these regulations is to make the PGx solutions more adaptable and focused toward oncology, pain management, central nervous system (CNS), Cardiovascular (CVD), and infectious diseases among others. The patients benefit indirectly from these regulations as it saves time and cuts down cost as the patients get the required treatment for the specific disease.

The market growth is propelled due to factors such as: rising usage in drug discovery processes, increasing demand for pharmacogenomics & precise drugs, technological innovation and advancement, increasing genetic disorder/abnormalities, and government support and regulations.

This study includes an overview and analysis of the PGx market, by type of ecosystem players ,type of therapeutics application, technology type, and geographical regions; allowing the researcher to develop a comprehensive outlook of the market. The PGx market report presents a detailed analysis of the key market dynamics and provides an extensive insight into various forms of developments, trends and key participants. All of the above mentioned report coverage parameters are discussed across different regions like North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW).

While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, compliances, and regulatory bodies, and their involvement in the PGx market. The research incorporates Porter’s Five Forces Model for in-depth analysis of the PGx market and an assessment of the factors governing it.

The answers to the following key questions can be found in the report:
- What are the major market drivers, challenges and opportunities of the PGx market and their use cases?
- What are the key trends and developments in the PGx market for genetic disease management?
- What are the key developmental strategies in different therapeutics across all regions?
- What are different types of PGx drugs and tests which are available in the market?
- How will the key market players leverage on key developments such as Mergers and Acquisitions, Partnerships, and Product Launch among others?
- Which geographical region will lead the global PGx market by the end of the forecast period?
- Which different technologies are used to develop PGx solutions?
- Who are the key players in the PGx market?
- What are the government regulations for different PGx solutions?
- What are different types of therapeutics in PGx market and which type of PGx product used in their treatment?
- What is the different used case scenarios considered under different therapeutic applications?
- What are the PGx market trends and key developments in different geographical regions?

The research deals with various aspects of the PGx market such as factors driving the market, its threats that can possibly slow down the market growth and the current growth opportunities that are going to shape the market expansion of PGx solutions. The research incorporates Porter’s Five Forces Model for in-depth analysis of the PGx market and an assessment of the factors governing it. The report builds itself upon a comprehensive value chain giving a clear understanding of ecosystem of PGx market penetration.

Towards the end of the report, the readers will have a clear understanding of the market dynamics, major drivers and the underlying threats and challenges that the global PGx market is subjected to, including the estimation of the industry’s growth in terms of production and revenue.

The report includes the profiles of major players in the PGx market that allows the readers to gain an insight into the various industry trends.

Executive Summary
The global Pharmacogenomics (PGx) market growth is gradually gaining speed as large number of government initiatives and research & development programs have been launched in the last few years. Advancement and innovation of new healthcare technologies such as next generation sequencing, High Throughput Screening (HTS), and Digital PCR are developing the platform for the growth of Pharmacogenomics (PGx) market. The global PGx market is expected to grow over $14.85 billion by 2022. The market growth is propelling due to factors such as: rising usage in drug discovery processes, increasing demand for pharmacogenomics & precise drugs, technological innovation and advancement, increasing genetic disorders/abnormalities, and government support and regulations.

The report has been further classified on the basis of ecosystem players, therapeutic applications, and geographical regions. Ecosystem is further segmented into: Pharmaceuticals companies, Diagnostic Companies, and Service Providers, which include Software & Healthcare database providers, Hospitals & Care Providers, and Insurance Providers.

Diagnostic Test segment is holding the maximum market share and is expected to grow at 11.63% CAGR from 2016 to 2022. This is due to the increasing demand for diagnostic tests as patients are emphasizing more on pre-diagnosis treatments, increasing genetic disorders & mutational diseases, and government initiatives and investment in research and development programs among others.

Observing current trends, Big Data companies included in service provider segments are collaborating and entering into partnerships with healthcare providers, academic institutions, pharmaceuticals and biotechnology companies to support the growth of the PGx market and thus, service segment is anticipated to grow at a high CAGR of 16.22% from 2016 to 2022. Moreover, the Pharmaceutical segment will also gain from traction of the patients due to increasing awareness about the benefits of PGx solutions and adoption of these solutions in developing regions.

With the increasing research and development process, it has been estimated that the demand for precision drugs will escalate in the coming future and thus result in the high growth of pharmaceutical & biotech companies.
The global PGx market on the basis of therapeutics is classified as cancer, cardiovascular, central nervous system, infectious diseases and other diseases. At present, Cancer is dominating the market and is expected to grow at a CAGR of 12.23% from 2016 to 2022, as the cases of cancer patients are increasing every year and thus, deployment of targeted therapeutics and diagnosis applications of cancer is also anticipated to increase tremendously.

The primarily reason attributed to the growth of the therapeutics market is due to the increase in cancer cases, cardiac diseases, skin diseases, HIV, mental disorders , and other genetic disorders. However, the infectious diseases are gaining more traction as compared to other diseases as the numbers of patients suffering from these diseases are increasing at a very rapid growth rate all over the world specifically in African and Asian countries. This segment is growing at a CAGR of 17.49% from 2016 to 2022.

In North America, existing players are integrating with new start-ups through partnerships and collaborations to capture the North American segment. North American local players are entering in other developing regions to acquire larger market share. Throughout the Asia-Pacific and European countries, regulatory bodies are rolling out regulations to keep a check on latest technologies.

North America is the largest contributor in the revenue generation in PGx market followed by Europe region, and is expected to grow at a high CAGR of 12.14% CAGR from 2016 to 2022. APAC region is expected to show the fastest growth globally, and is expected to grow at 18.74% CAGR from 2016 to 2022.

The APAC region is focusing more on technological development and introduction of new gene sequencing and gene mapping tools into healthcare systems to develop specific laboratory diagnostic tests.

Countries Covered
North America, Europe, Asia Pacific, Rest of The World